Product Image

Ideal Omega 3 Orange Flavored

Barlean's Organic Oils
4.8
★ ★ ★ ★ ★
(113 ratings)
EPA (Eicosapentaenoic Acid) 750 mg
Omega-3 60 mg
DHA 250 mg
Product Image
Score74
A convenient high-EPA omega-3 with useful DHA, limited by sparse source details and a profile that is less suited to DHA-led goals.
How scoring works
Quantity:30 Softgel(s) • (30 servings)
Goals:
Heart Health
Vision Support
Mental Focus

Score 74

A convenient high-EPA omega-3 with useful DHA, limited by sparse source details and a profile that is less suited to DHA-led goals.
How scoring works
$28.99($0.96 per serving)
iHerb
$ 28.99
Pure Formulas
$ 28.99
Report prices

Analysis

EPA dominates the omega-3 profile, making the formula especially relevant to cardiovascular and inflammatory-balance support. DHA adds useful structural support for the brain and retina, but its amount is smaller than the EPA contribution.

EPA, DHA, and other omega-3s are disclosed individually, which gives clear active dosing. The supplied label does not name the oil source or molecular form and gives an unusable total polyunsaturated-fat entry, reducing confidence in full label quality.

Adults wanting a high-EPA, one-softgel product may find it convenient. People seeking DHA-centered vision or cognitive support should choose a formula with a larger DHA share and clearer source information.

Who is it for
  • Adults seeking EPA-forward heart support
  • People who prefer one flavored softgel per day
Best for
  • Cardiovascular omega-3 support
  • High-EPA supplementation

Pros

  • Strong EPA amount
  • DHA and other omega-3s are disclosed
  • One-softgel serving
  • Concentrated fatty-acid profile

Cons

  • Oil source is not stated in the supplied data
  • Molecular form is missing
  • DHA is modest relative to EPA
  • No freshness or oxidation details

Warnings

  • Confirm the oil source before use if fish or seafood allergy is present
  • EPA and DHA may add to bleeding tendency with anticoagulant or antiplatelet medicines
  • Omega-3 softgels can cause reflux or fishy aftertaste
  • Review total omega-3 intake before surgery

Nutrient quality

83 Highest impact

Strong EPA and moderate DHA amounts provide meaningful omega-3 depth for the intended uses. Missing oil source, molecular form, and oxidation-protection details weaken quality confidence.

Ingredient transparency

79 High impact

EPA and DHA have clear amounts, and no blend hides the key fatty-acid doses. Source, molecular-form, daily-direction, and inactive-ingredient details remain incomplete.

Customer satisfaction

67 High impact

The supplied aggregate rating is favorable and supported by a moderate review volume. Detailed feedback is unavailable, so repeated complaints and fit with the intended use cannot be judged.

Value for money

62 Moderate impact

The formula provides moderate practical value for its key fatty-acid content. The focused active profile preserves category competitiveness.

Report analysis

Goals

Heart Health
Heart Health
Impact
Highest effect
A+ Goal FitA+ Strength of SupportB CoverageA+ Formula Quality
EPA (Eicosapentaenoic Acid) · 750 mg

A fully disclosed 750 mg of EPA and 250 mg of DHA provides a concentrated omega-3 serving with strong heart-health relevance. The EPA-forward profile directly supports triglyceride management and also contributes to inflammatory balance.

One softgel delivers the full active amount without a vague fish-oil total, making potency easy to judge. EPA and DHA may modestly increase bleeding tendency with anticoagulant or antiplatelet medicines, especially when combined with other products that affect clotting.

Study evidence
Vision Support
Vision Support
Impact
Highest effect
B Goal FitA- Strength of SupportC CoverageA+ Formula Quality
EPA (Eicosapentaenoic Acid) · 750 mg

A strong EPA amount supports ocular-surface balance, while DHA contributes to retinal membrane structure. The combination is highly relevant but still lacks carotenoid light filtration and antioxidant vitamins.

Both fatty acids are individually quantified at meaningful amounts in a one-softgel serving. The supplied data does not identify the fatty-acid form or oxidation controls.

Study evidence
Mental Focus
Mental Focus
Impact
High effect
C Goal FitB+ Strength of SupportD CoverageB+ Formula Quality

EPA and DHA provide long-term support for brain structure and a healthy inflammatory balance, but they are not direct acute focus enhancers. The disclosed amounts are substantial and may support the conditions needed for steady cognition over time.

The formula does not address alertness, neurotransmitter production, or stress resilience with dedicated focus ingredients. Exact fatty-acid amounts are helpful, although the oil form and oxidation-quality details are not provided.

Study evidence

Ingredients

IngredientAmount per serving
Calories
15 Calorie(s)
Total Fat
1 Gram(s)
Omega-3 Polyunsaturated Fat
0 NP
Eicosapentaenoic Acid
750 mg
Docosahexaenoic Acid
250 mg
Other Omega-3 Fatty Acids
60 mg
Adults 18–50
Report overview
EPA (Eicosapentaenoic Acid) · 750 mg OverallScore60
C- Active Ingredient Quality & BioavailabilityB- Dose, Safety & Label TransparencyD+ Value

The molecular form is unspecified; ePA density is highly concentrated, and no protective antioxidant is listed. The serving provides a strong EPA amount with a clearly EPA-centric ratio. No purification or third-party verification is shown, while normalized cost is moderate.

View ingredientView products
Omega-3 · 60 mg OverallScore49
F Active Ingredient Quality & BioavailabilityB- Dose, Safety & Label TransparencyD+ Value

EPA and DHA are clearly disclosed and together make up most of the serving's oil. The molecular form, oil source, antioxidant protection, and independent purity testing are not provided. The cost per active amount is moderate despite the high concentration.

View ingredientView products
DHA · 250 mg OverallScore21
F Active Ingredient Quality & BioavailabilityF Dose, Safety & Label TransparencyF Value

The DHA chemical form is not identified, leaving bioavailability uncertain. The 250 mg DHA serving provides a moderate amount. No protective antioxidant is listed, and an unspecified source lacks explicit third-party purity verification.

View ingredientView products
Loading alternative details
86 Performance

Omega-3 Triglyceride Fish Oil 1100 mg

NATURELO Premium Supplements
A formulation advantage for the right user over Ideal Omega 3 Orange Flavored is a highly concentrated 1,100 mg triglyceride omega-3 serving with clear EPA and DHA amounts. Molecular distillation adds purity assurance, though fish species, antioxidant protection, and independent testing are not stated.
86 Performance

Purified & Clear Omega 3 Fish Oil 1000 mg

Doctor's Best
A formulation advantage for the right user over Ideal Omega 3 Orange Flavored is a substantial serving with EPA and DHA stated separately. The ethyl-ester form is less readily absorbed than triglyceride oil, and oxidation protection plus independent testing are not supplied.
84 Performance

Wild Alaskan Fish Oil Peak Omega-3 Liquid Natural Lemon Flavor

Wiley's Finest
A formulation advantage for the right user over Ideal Omega 3 Orange Flavored is a high liquid serving with substantial EPA and DHA stated separately. The intake deserves care with anticoagulant or antiplatelet medicines, while molecular-form, oxidation, and purity details are missing.
79 Budget

Fish Oil 1000 mg

Mason Natural
Lower recurring cost is the clearest advantage over Ideal Omega 3 Orange Flavored, while the formula provides clearly disclosed EPA and DHA in a basic fish-oil softgel. The active omega-fat amount is low, and source, molecular form, oxidation protection, and purity testing are not supplied.
82 Budget

Omega 3 Fish Oil Concentrate

Solgar
Lower recurring cost is the clearest advantage over Ideal Omega 3 Orange Flavored, while the formula provides a modest, clearly disclosed EPA and DHA serving for routine use. Low concentration plus missing molecular-form, source, oxidation, and purity details limit quality confidence.
69 Budget

Kid's Chewable DHA 100 mg Bursting Orange Flavor!

Carlson
Lower recurring cost is the clearest advantage over Ideal Omega 3 Orange Flavored, while the formula provides triglyceride fish oil and vitamin E in a child-friendly chewable with 100 mg DHA. The active omega-3 amount and oil concentration are low, and independent purity testing is not supplied.
84 Value

Omega-3 Fish Oil 1250 mg

SR Sports Research
Lower recurring cost paired with a highly concentrated EPA-led fish-oil serving in one softgel creates a useful value trade-off versus Ideal Omega 3 Orange Flavored. Molecular form, purification, antioxidant protection, fish species, and independent testing are not supplied.
84 Value

Fish Oil 1400 mg

Nature's Bounty
Lower recurring cost paired with a meaningful EPA-led amount with strong oil concentration creates a useful value trade-off versus Ideal Omega 3 Orange Flavored. The ethyl-ester form is less readily absorbed, and fish source, antioxidant protection, and independent testing are not stated.
84 Value

Omega 3 Fish Oil Concentrate

Solgar
Lower recurring cost paired with triglyceride fish oil with individual fatty acids clearly disclosed creates a useful value trade-off versus Ideal Omega 3 Orange Flavored. Active concentration is modest, while source, oxidation protection, and independent purity details are missing.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone.
    Doshi R; Kumar A; Thakkar S; Shariff M; Adalja D; Doshi A; Taha M; Gupta R; Desai R; Shah J; Gullapalli N · The American journal of cardiology · 2020
    Meta-analysis27,415 participants5 studies pooledHeart Health forEPA (Eicosapentaenoic Acid)
  2. Effect of omega-3 long-chain polyunsaturated fatty acid supplementation on heart rate: a meta-analysis of randomized controlled trials.
    Hidayat K; Yang J; Zhang Z; Chen GC; Qin LQ; Eggersdorfer M; Zhang W · European journal of clinical nutrition · 2019
    Meta-analysis3,000 participants51 studies pooledHeart Health forEPA (Eicosapentaenoic Acid)
  3. Long-Chain Polyunsaturated Fatty Acids Are Associated with Blood Pressure and Hypertension over 10-Years in Black South African Adults Undergoing Nutritional Transition.
    Zec MM; Schutte AE; Ricci C; Baumgartner J; Kruger IM; Smuts CM · Foods (Basel, Switzerland) · 2020
    Cohort study300 participantsHeart Health forEPA (Eicosapentaenoic Acid)
  4. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
    Yokoyama M; Origasa H; Matsuzaki M; Matsuzawa Y; Saito Y; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K; Japan EPA lipid intervention study (JELIS) Investigators · Lancet (London, England) · 2007
    Randomized trial18,645 participantsHeart Health forEPA (Eicosapentaenoic Acid)
  5. The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review.
    Innes JK; Calder PC · International journal of molecular sciences · 2018
    Systematic review527 participants6 studies pooledHeart Health forEPA (Eicosapentaenoic Acid)
  6. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis.
    Dinu M; Sofi F; Lotti S; Colombini B; Mattioli AV; Catapano AL; Casula M; Baragetti A; Wong ND; Steg PG; Ambrosio G · European journal of preventive cardiology · 2024
    Meta-analysis134,144 participants18 studies pooledHeart Health forEPA (Eicosapentaenoic Acid)
  7. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).
    Saito Y; Yokoyama M; Origasa H; Matsuzaki M; Matsuzawa Y; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K; JELIS Investigators, Japan · Atherosclerosis · 2008
    Randomized trial14,981 participantsHeart Health forEPA (Eicosapentaenoic Acid)
  8. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids.
    Grimsgaard S; Bonaa KH; Hansen JB; Nordøy A · The American journal of clinical nutrition · 1997
    Randomized trial234 participantsHeart Health forEPA (Eicosapentaenoic Acid)
  9. Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease.
    Toyama K; Nishioka T; Isshiki A; Ando T; Inoue Y; Kirimura M; Kamiyama T; Sasaki O; Ito H; Maruyama Y; Yoshimoto N · Cardiovascular drugs and therapy · 2014
    Randomized trial80 participantsHeart Health forEPA (Eicosapentaenoic Acid)
  10. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome.
    Satoh N; Shimatsu A; Kotani K; Himeno A; Majima T; Yamada K; Suganami T; Ogawa Y · Hypertension research : official journal of the Japanese Society of Hypertension · 2010
    Randomized trial92 participantsHeart Health forEPA (Eicosapentaenoic Acid)
  11. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
    Matsuzaki M; Yokoyama M; Saito Y; Origasa H; Ishikawa Y; Oikawa S; Sasaki J; Hishida H; Itakura H; Kita T; Kitabatake A; Nakaya N; Sakata T; Shimada K; Shirato K; Matsuzawa Y; JELIS Investigators · Circulation journal : official journal of the Japanese Circulation Society · 2009
    Randomized trialHeart Health forEPA (Eicosapentaenoic Acid)
  12. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
    Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology · Circulation · 2020
    OtherHeart Health forEPA (Eicosapentaenoic Acid)
  13. The influence of n-3 polyunsaturated fatty acids on cognitive function in individuals without dementia: a systematic review and dose-response meta-analysis.
    Suh SW; Lim E; Burm SY; Lee H; Bae JB; Han JW; Kim KW · BMC medicine · 2024
    Meta-analysis9,660 participants24 studies pooledMental Focus forEPA (Eicosapentaenoic Acid)
  14. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD.
    Gustafsson PA; Birberg-Thornberg U; Duchén K; Landgren M; Malmberg K; Pelling H; Strandvik B; Karlsson T · Acta paediatrica (Oslo, Norway : 1992) · 2011
    Randomized trial92 participantsMental Focus forEPA (Eicosapentaenoic Acid)
  15. Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)-Should They Be Mandatory Supplements in Pregnancy?
    Amza M; Haj Hamoud B; Sima RM; Dinu MD; Gorecki GP; Popescu M; Gică N; Poenaru MO; Pleș L · Biomedicines · 2024
    Narrative reviewMental Focus forEPA (Eicosapentaenoic Acid)
  16. Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials.
    Patan MJ; Kennedy DO; Husberg C; Hustvedt SO; Calder PC; Khan J; Forster J; Jackson PA · The American journal of clinical nutrition · 2021
    Randomized trial310 participantsMental Focus forEPA (Eicosapentaenoic Acid)
  17. Dietary omega-3 LCPUFA intake in the prevention of neovascular age-related macular degeneration: a systematic review and meta-analysis.
    Meng XT; Shi YY; Hong-Yan Z · Nutricion hospitalaria · 2022
    Meta-analysis5 studies pooledVision Support forEPA (Eicosapentaenoic Acid)
  18. Dietary omega-3 polyunsaturated fatty acids and fish intake and risk of age-related macular degeneration.
    Jiang H; Shi X; Fan Y; Wang D; Li B; Zhou J; Pei C; Ma L · Clinical nutrition (Edinburgh, Scotland) · 2022
    Meta-analysis21 studies pooledVision Support forEPA (Eicosapentaenoic Acid)
  19. Dietary fatty acid intake, plasma fatty acid levels, and the risk of age-related macular degeneration (AMD): a dose-response meta-analysis of prospective cohort studies.
    Zhong Y; Wang K; Jiang L; Wang J; Zhang X; Xu J; Yao K · European journal of nutrition · 2021
    Meta-analysis167,581 participants11 studies pooledVision Support forEPA (Eicosapentaenoic Acid)
  20. Dietary ω-3 fatty acid and fish intake and incident age-related macular degeneration in women.
    Christen WG; Schaumberg DA; Glynn RJ; Buring JE · Archives of ophthalmology (Chicago, Ill. : 1960) · 2011
    Cohort study38,022 participantsVision Support forEPA (Eicosapentaenoic Acid)
  21. Can Omega-3 Fatty Acids Serve as a Preventive Strategy for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis.
    Chen KY; Chan HC; Chan CM · The Journal of nutrition · 2026
    Meta-analysis18 studies pooledVision Support forEPA (Eicosapentaenoic Acid)